Figure 7
Effects of intravenous injection of purified EVs released from HLSCs. (A-B) Representative micrographs of renal tissues of healthy mice (A) and of AKI mice (B) treated with Dil labeled EVs (red), five hours after the injection. Original magnification: ×630. Nuclei were stained in blue with Hoechst and laminin in green. (C) Creatinine and (D) BUN values on day 5 after glycerol administration. Data are expressed as mean ± SD; ANOVA with Dunnet’s multicomparison test was performed: *P <0.05 EV-treated AKI mice versus vehicle-treated AKI mice. (E) Representative micrographs of renal histology of control healthy mice (ctrl) or AKI mice at day 5 after glycerol administration intravenously injected with vehicle alone (AKI + vehicle) or with EVs derived from 3.5 × 105 HLSCs (EV1) or from 10 × 105 HLSCs (EV2). Original magnification: ×400. (F) Comparison of HLSC-derived EV injection on tubular morphology at day 5 after AKI induction. Data are expressed as mean ± SD of hyaline casts and necrotic tubules observed under high power (original magnification: ×400). ANOVA with Dunnet’s multicomparison test was performed: *P <0.05 EV-treated AKI mice versus vehicle-treated AKI mice. (G) Quantification of PCNA-positive cells/hpf in AKI mice untreated or treated with HLSC-derived EVs after five days of AKI. Data are expressed as mean ± SD; ANOVA with Dunnet’s multicomparison test: *P <0.05 EV- treated AKI mice versus vehicle- treated AKI mice. AKI, acute kidney injury; ANOVA, analysis of variance; BUN, blood urea nitrogen; CM, conditioned medium; EV, extracellular vesicles; HLSCs, human liver stem cells; hpf, high power field; PCNA, proliferating cell nuclear antigen; SD, standard deviation.